Feature Channels: Kidney Disease

Filters close
access_time Embargo lifts in 2 days
This news release is embargoed until 25-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 4:10 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 25-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 4:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 26-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 3:55 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 25-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 3:50 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 26-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 3:50 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 26-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 3:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 25-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 3:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 25-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 3:35 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 25-Oct-2024 1:30 PM EDT Released to reporters: 18-Oct-2024 3:35 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 25-Oct-2024 1:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 26-Oct-2024 1:30 PM EDT Released to reporters: 18-Oct-2024 3:25 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Oct-2024 1:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 24-Oct-2024 7:30 PM EDT Released to reporters: 18-Oct-2024 3:25 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 24-Oct-2024 7:30 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 27-Oct-2024 12:00 PM EDT Released to reporters: 18-Oct-2024 3:15 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 27-Oct-2024 12:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
Newswise: Study Finds HIV-To-HIV Kidney Transplants Are as Safe and Effective as Those Using Organs From Donors Without HIV
Released: 16-Oct-2024 5:15 PM EDT
Study Finds HIV-To-HIV Kidney Transplants Are as Safe and Effective as Those Using Organs From Donors Without HIV
 Johns Hopkins Medicine

According to findings from a multicenter study led by Johns Hopkins Medicine and released today in The New England Journal of Medicine (NEJM), transplanting kidneys from deceased donors who had the human immunodeficiency virus (HIV) to recipients with HIV is safe. Perhaps more importantly, the study authors also found that HIV-to-HIV kidney transplants are comparable in effectiveness to those using organs from donors without HIV.

Comment
Newswise: Non-Invasive Eye Test for Multiple Diseases to Advance Under $4.8m NIH Award
Released: 11-Oct-2024 3:05 PM EDT
Non-Invasive Eye Test for Multiple Diseases to Advance Under $4.8m NIH Award
Indiana University

Researchers at the IU School of Optometry and IU Luddy School of Informatics, Computing and Engineering will advance next-generation technology that uses a simple eye scan to assist in the early detection of conditions such as Alzheimer’s disease, diabetes and heart disease.

Comment
Newswise: Study Shows Use of a Gene Could Halt Diabetic Kidney Disease
Released: 9-Oct-2024 12:05 PM EDT
Study Shows Use of a Gene Could Halt Diabetic Kidney Disease
Stony Brook University

New research by Stony Brook Medicine nephrology specialists that centers on targeting key cellular signaling between two types of kidney cells, and inducing a certain gene within those processes, may help prevent or reduce the progression of diabetic kidney disease (DKD), the leading cause of chronic kidney disease worldwide.

Comment
Newswise: New Imaging Technique Accurately Detects Aggressive Kidney Cancer
Released: 3-Oct-2024 10:05 AM EDT
New Imaging Technique Accurately Detects Aggressive Kidney Cancer
 University of California, Los Angeles (UCLA), Health Sciences

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer.

Comment
Released: 2-Oct-2024 10:05 AM EDT
From Replicant's Dream to Reality: Imaging AI Extending Lives
 Perelman School of Medicine at the University of Pennsylvania

A new AI tool is providing a sci-fi level of precision to physicians reviewing images of people’s livers, spleens, kidneys, and more to determine with some exactitude if they are showing any abnormal traits that could shorten a person’s life

Comment
   
Released: 1-Oct-2024 2:05 PM EDT
American Society of Nephrology Launches the Glomerular Diseases Collaborative (Gd-C) to Address Gaps in Knowledge and Barriers in the Care of People with Glomerular Diseases
 American Society of Nephrology (ASN)

Chronic kidney disease is a progressive condition that affects more than 10% of the general population worldwide, amounting to 800 million individuals.1 Glomerular diseases (GD), excluding diabetic nephropathy, account for approximately 25% of the cases of kidney diseases worldwide.2 Given the magnitude of long-term morbidity from GD— particularly the frequent manifestation in younger patients—diagnosing it efficiently and optimizing management to control diseases and prevent progressive kidney diseases is paramount.

Comment

Not for public release

This news release is embargoed until 30-Sep-2024 5:00 PM EDT Released to reporters: 24-Sep-2024 2:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 30-Sep-2024 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
Released: 30-Sep-2024 8:35 AM EDT
Kidney Week 2024 to Explore a World Without Kidney Diseases
 American Society of Nephrology (ASN)

Largest Global Gathering of Kidney Professionals Expands Program to Include More Breaking Research and Focused Discussions on Key Public Health and Policy Issues

Comment


close
2.33767